Enhanced CAR T cell therapy offers new strategy for lymphoma

A new study from Penn Medicine marks a significant development in the ongoing evolution of CAR T cell therapy, as a novel cytokine-enhanced CAR T that has been tested in patients with blood cancer shows robust response rates. Led by Jakub Svoboda, Carl June, and a team of researchers at the Perelman School of Medicine, a next-generation “armored” CAR T cell therapy showed promising results in a small cohort of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. “I’m thrilled that this new generation of CAR T cell therapy, created here at Penn, was highly effective in patients who have already tried everything available to treat their lymphoma,” says Svoboda.